CIRM Delays Action on Clinical Trials, Biotech Loan Changes
The California stem cell agency today said its directors would put off until their March meeting a discussion of a proposed foray into financing of clinical trials.
CIRM also said that directors would not vote this week on changes in its $500 million biotech loan program. Instead they are expected to act later on the proposal during a special telephonic …
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.